molecules of the month

BAY 1101042 (runcaciguat)

oral once-daily sGC activator

Ph. II for CKD + diabetic neuropathy

from cell-based HTS + opt

J. Med. Chem., Apr. 19, 2021

Bayer AG, Wuppertal, DE

1 min read

The Bayer soluble guanylate cyclase (sGC) activator, BAY 1101042 (runcaciguat), is a once-daily (50 mg), oral clinical candidate in Ph. II for chronic kidney disease and diabetic retinopathy. sGC is an intracellular receptor for nitric oxide (NO), binding NO via a heme-cofactor, which activates a catalytic domain that leads to production of second messenger cGMP. This NO-sGC-cGMP axis is a key pathway regulating the cardiovascular system. Runcaciguat acts by displacing the heme- cofactor, but binding in a way that activates sGC as if NO had bound heme, turning on cGMP production. This conveniently dosed candidate can be useful in evaluating the NO-sGC-cGMP axis in humans in multiple disease contexts.

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: